UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  ------------

                                    FORM 6-K

                                  ------------

                            REPORT OF FOREIGN ISSUER

                       Pursuant to Rule 13a-16 or 15d-16
                     of the Securities Exchange Act of 1934


                                February 10, 2009


                                  ------------

                                NOVO NORDISK A/S
             (Exact name of Registrant as specified in its charter)


                                    NOVO ALLE
                               DK-2880, BAGSVAERD
                                     DENMARK
                    (Address of principal executive offices)

                                  ------------

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F

                       Form 20-F [X]     Form 40-F [ ]


Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                             Yes [ ]     No [X]


If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________



NOVO NORDISK FILES ANNUAL REPORT WITH THE SEC

NOVO NORDISK A/S HAS FILED ITS ANNUAL REPORT 2008 ON FORM 20-F FOR THE FINANCIAL
YEAR 2008 WITH THE US SECURITIES AND EXCHANGE COMMISSION (SEC), INCORPORATING BY
REFERENCE THE NOVO NORDISK A/S ANNUAL REPORT 2008. THE REPORTS ARE AVAILABLE AT
THE SEC'S WEBSITE, WWW.SEC.GOV AS WELL AS AT: NOVONORDISK.COM - INVESTORS -
DOWNLOAD CENTRE (LISTED UNDER 2008).

Shareholders and ADR holders may receive a hard copy of the annual reports free
of charge upon request by filling out a request form at
novonordisk.com/investors/download-centre or upon request to either tel no (609)
919 7937 or by e-mail to hrmm@novonordisk.com. When e-mailing, please state the
exact mailing address and the document(s) you wish to receive.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81
countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.

Further information
Media:                      Investors:

Outside North America:      Outside North America

Mike Rulis                  Mads Veggerby Lausten
Tel: (+45) 4442 3573        Tel: (+45) 4443 7919
mike@novonordisk.com        mlau@novonordisk.com

                            Kasper Roseeuw Poulsen
                            Tel: (+45) 44424471
                            krop@novonordisk.com


In North America:           In North America

Sean Clements               Hans Rommer
Tel: (+1) 609 514 8316      Tel: (+1) 609 919 7937
secl@novonordisk.com        hrmm@novonordisk.com



                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf of the
undersigned, thereunto duly authorized.

Date: February 10, 2009                         NOVO NORDISK A/S
                             ---------------------------------------------------
                                            Lars Rebien Sorensen,
                                     President and Chief Executive Officer